Laurus Labs Q4 Review - Upbeat Numbers Trend Continues: ICICI Direct
An employee holds metformin pills at a Laurus Labs Ltd. pharmaceutical plant in Visakhapatnam, Andhra Pradesh, India. (Photographer: Sara Hylton/Bloomberg)

Laurus Labs Q4 Review - Upbeat Numbers Trend Continues: ICICI Direct

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Laurus Labs Ltd.'s Q4 revenue grew 68.3% to Rs 1,412 crore with strong growth across segments.

Results were driven by 88% year-on-year jump in active pharmaceutical ingredient segment to Rs 797 crore amid strong traction in antiviral APIs to Rs 569 crore (2.1 times YoY) driven by higher volume of first and second line products.

Formulations revenue grew 60.9% YoY to Rs 430 crore on the back of higher tender business from low-to-middle income countries and higher volumes from the U.S. and Europe.

Contract research and manufacturing services business grew 19.0% YoY to Rs 176 crore.

Click on the attachment to read the full report:

ICICI Direct Laurus Labs Q4FY21 Result Review.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.